English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Biogen Announces New Updates Across Its SMA Research Program at 2022 MDA Conference
Biogen Inc. announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies. These updates were presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13-16, 2022).
First Patient Treated in Phase 3b ASCEND Study
The ASCEND study is currently enrolling with the first patient treated in Q1 2022. At the conference, Biogen presented the design of the open-label, global Phase 3b study to evaluate the potential benefit of investigational higher dose nusinersen in later-onset, non-ambulatory SMA patients previously treated with Evrysdi® (risdiplam).
“As the SMA community gains more experience with available therapies, we are gleaning new insights about how these treatments can enhance the lives of individuals impacted by SMA. However, unmet needs still remain for the community,” said Basil Darras, M.D., Professor of Neurology at Harvard Medical School and Director of the Neuromuscular Center and Spinal Muscular Atrophy Program at Boston Children’s Hospital. “The ASCEND study seeks to generate data that have the potential to inform decisions regarding treatment for our patients with later-onset SMA.”
BookmarkRelated Content
-
Parent Perceptions in Choosing Treatment for Infants With Spinal Muscular Atrophy Diagnosed Through Newborn Screenin...Objective: To identify factors parents c...
-
Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type ISpinal muscular atrophy (SMA) is a neuro...
-
Kristin J. Krosschell, DPTKristin J. Krosschell, DPT is the Profes...
-
SMA Treatments and Continuing the FightFor so many years, patients and their fa...
-
Lunch & Learn: Gene Therapy for SMAhttps://www.youtube.com/watch?v=YFEMR1ZH...
-
A Caregiver’s Guide to ZolgensmaIndication ZOLGENSMA® (onasemnogene abe...
-
Spinal Muscular Atrophy 2020: SMA Medications for Treatment Updateshttps://www.youtube.com/watch?v=dnSXnvrO...
Powered by
In partnership with
